2023 LIFE SCIENCES DIGITAL PATHOLOGY ADOPTION SURVEY
New research commissioned by Proscia asked 40 senior executives at the top 150 pharma companies and leading contract research organizations about their use of digital pathology, the benefits it has delivered, and its future impacts.
The results collectively indicate a growing need to unify teams, applications (including AI), and pathology data with a modern software platform that drives all stages of R&D across the connected enterprise.
Download the survey report to learn how the respondents viewed:
- The state of digital pathology adoption in life sciences
- Top reasons for going digital
- The growing use of AI to drive efficiency and quality gains
Get Your Copy
Digital pathology has earned its spot on the life sciences C-suite agenda
Digital pathology is empowering today’s research teams with tools — including artificial intelligence — that deliver on the promise of precision medicine.
How extensively have life sciences organizations adopted digital pathology? Where have they seen the greatest benefits, and what does the future hold? That’s what this survey aimed to discover.
Get the full survey report!
About Proscia
Proscia is a software company that is accelerating pathology’s transformation toward a data-driven discipline. Our Concentriq® digital pathology platform and powerful AI applications are unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care.